Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis
NCT00012467 is registered in ClinicalTrials.gov with InterMune as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase II Study of the Safety and Antifungal Activity of Subcutaneous Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) in Conjunction With Standard Therapy in Patients With Acute Cryptococcal Meningitis
- Lead sponsor
- InterMune
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2000
- Completion date
- July 31, 2001
- Enrollment
- 60
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.